Form 4: Guardant Health Director Sells Shares After RSU Vesting

Guardant Health Director Tariq Musa reported the acquisition of common stock through RSU vesting and a subsequent sale of a portion of his holdings.

Summary

• Director Tariq Musa acquired 249 shares of Guardant Health Common Stock on September 15, 2025, through the vesting of Restricted Stock Units (RSUs) at a price of $0.
• Following this acquisition, Tariq Musa beneficially owned 7,707 shares of Common Stock.
• On September 17, 2025, Tariq Musa sold 116 shares of Guardant Health Common Stock at a price of $55.63 per share.
• After the reported transactions, Tariq Musa beneficially owns 7,591 shares of Common Stock and 4,498 Restricted Stock Units.
• The reported transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading schedule.
• The Restricted Stock Unit award, granted on March 6, 2023, vests over a four-year period, with 25% vesting on March 15, 2024, and the remaining 75% vesting monthly over the subsequent three years.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting and a pre-planned sale) which are generally neutral in sentiment, though insider selling can sometimes be viewed with slight caution.

Positives

• The vesting of 249 Restricted Stock Units represents a compensation event for Director Tariq Musa, converting equity awards into common stock.
• The transaction was executed under a Rule 10b5-1(c) plan, which can mitigate concerns about opportunistic insider trading by demonstrating a pre-scheduled sale.

Negatives

• The sale of 116 shares by a director, even if pre-planned, could be perceived negatively by some investors as a reduction in insider ownership.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes lead to negative market sentiment or speculation regarding the company's future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders may observe the director's sale of shares, which could lead to minor shifts in sentiment, although the pre-planned nature (10b5-1) typically mitigates significant negative interpretations.

Key Dates

Keywords

Guardant Health, GH, Form 4, Insider Trading, Stock Sale, RSU Vesting, Tariq Musa, Director Transaction, 10b5-1 Plan